Cassava Sciences (SAVA) News Today $26.91 +0.77 (+2.95%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period A High-potential Bull Put Strategy on Cassava SciencesNovember 12, 2024 | msn.comAnavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's DiseaseNovember 11, 2024 | seekingalpha.comCassava Sciences, Inc. (NASDAQ:SAVA) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comCassava Sciences' (SAVA) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $116.00 price target on shares of Cassava Sciences in a research note on Friday.November 8, 2024 | marketbeat.comCassava Sciences (NASDAQ:SAVA) Releases Quarterly Earnings Results, Beats Estimates By $0.79 EPSCassava Sciences (NASDAQ:SAVA - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.79. During the same period in the prior year, the company posted ($0.61) earnings per share.November 8, 2024 | marketbeat.comCassava Sciences: With Almost Half The Float Shorted, Results Could Be InterestingNovember 8, 2024 | seekingalpha.comCassava Sciences’ Q3 2024: Financials and Alzheimer’s Trials ProgressNovember 8, 2024 | markets.businessinsider.comCassava Sciences, Inc. (SAVA) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comLooking At Cassava Sciences's Recent Unusual Options ActivityNovember 7, 2024 | benzinga.comCassava Sciences beats in Q3 ahead of key Alzheimer’s readoutNovember 7, 2024 | msn.comCassava Q3 Earnings Review: It Feels Like The End May Be NighNovember 7, 2024 | seekingalpha.comCassava Sciences Reports Q3 2024 Financial and Operating ResultsNovember 7, 2024 | globenewswire.comUnpacking the Latest Options Trading Trends in Cassava SciencesNovember 6, 2024 | benzinga.comCassava Sciences (NASDAQ:SAVA) Trading Down 5.8% - Should You Sell?Cassava Sciences (NASDAQ:SAVA) Trading Down 5.8% - Here's What HappenedNovember 5, 2024 | marketbeat.comCassava Sciences (SAVA) Scheduled to Post Earnings on ThursdayCassava Sciences (NASDAQ:SAVA) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comCassava Sciences put volume heavy and directionally bearishOctober 31, 2024 | markets.businessinsider.comCassava Sciences to Report Third Quarter 2024 Results on November 7, 2024October 31, 2024 | globenewswire.com36,052 Shares in Cassava Sciences, Inc. (NASDAQ:SAVA) Bought by International Assets Investment Management LLCInternational Assets Investment Management LLC acquired a new position in shares of Cassava Sciences, Inc. (NASDAQ:SAVA - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 36,052 shares of theOctober 31, 2024 | marketbeat.comAnalysts Believe Cassava Sciences Now Has 300% Upside From HereCassava Sciences faces controversy over its Alzheimer's drug, simufilam, amid fraud allegations, yet analysts maintain a Buy rating with high upside potential.October 30, 2024 | marketbeat.comCassava Sciences call volume above normal and directionally bullishOctober 23, 2024 | markets.businessinsider.comCassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The EdgeOctober 17, 2024 | msn.comCassava Sciences (NASDAQ:SAVA) Trading 5.1% Higher - What's Next?Cassava Sciences (NASDAQ:SAVA) Shares Up 5.1% - Still a Buy?October 14, 2024 | marketbeat.comEquities Analysts Offer Predictions for Cassava Sciences, Inc.'s FY2025 Earnings (NASDAQ:SAVA)Cassava Sciences, Inc. (NASDAQ:SAVA - Free Report) - Research analysts at HC Wainwright issued their FY2025 EPS estimates for Cassava Sciences in a research report issued to clients and investors on Tuesday, October 8th. HC Wainwright analyst V. Bernardino forecasts that the company will post earOctober 10, 2024 | marketbeat.comHC Wainwright & Co. Upgrades Cassava Sciences (SAVA)October 9, 2024 | msn.com$1000 Invested In This Stock 5 Years Ago Would Be Worth $20,000 TodayOctober 9, 2024 | benzinga.comCassava Sciences Advances Alzheimer’s Trials Amid SEC SettlementOctober 9, 2024 | finance.yahoo.comCassava Sciences: Phase III trials storm ahead amid controversyOctober 9, 2024 | finance.yahoo.comCassava Sciences earns rare buy as H.C. Wainwright upgrades post settlementOctober 8, 2024 | msn.comWhat's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?October 8, 2024 | finance.yahoo.comCassava Sciences (NASDAQ:SAVA) Shares Gap Up - What's Next?Cassava Sciences (NASDAQ:SAVA) Shares Gap Up - What's Next?October 8, 2024 | marketbeat.comCassava Sciences (NASDAQ:SAVA) Upgraded to "Buy" at HC WainwrightHC Wainwright raised Cassava Sciences from a "neutral" rating to a "buy" rating and set a $116.00 price target for the company in a report on Tuesday.October 8, 2024 | marketbeat.comOfficials Cast Doubt on a Dementia Drug, but Human Trials ContinueOctober 3, 2024 | nytimes.comCassava's Alzheimer's Therapy: A Confidence BetOctober 2, 2024 | seekingalpha.comWhy Cassava Sciences Stock Dived by Almost 11% TodaySeptember 27, 2024 | fool.comCassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's ClaimsSeptember 27, 2024 | investopedia.comCassava Sciences Resolves SEC InvestigationSeptember 26, 2024 | globenewswire.comUS charges Cassava Sciences, two former executives for misleading claims about Alzheimer's clinical trialSeptember 26, 2024 | reuters.comWhy I'm Avoiding Cassava Stock For NowSeptember 25, 2024 | seekingalpha.comDebate rages over push for new green revolution in Africa's agricultureSeptember 25, 2024 | reuters.comCassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 TrialsSeptember 24, 2024 | msn.comCassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 TrialsSeptember 24, 2024 | globenewswire.comCassava Sciences Unusual Options Activity For September 23September 23, 2024 | benzinga.comCassava Sciences, Inc. (NASDAQ:SAVA) Shares Purchased by Bank of New York Mellon CorpBank of New York Mellon Corp boosted its position in Cassava Sciences, Inc. (NASDAQ:SAVA - Free Report) by 18.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 140,847 shares of the company's stock after purchasing an additional 2September 19, 2024 | marketbeat.comFederal Reserve expected to cut rates for first time in 4 years: Yahoo FinanceSeptember 18, 2024 | finance.yahoo.comCassava Sciences (NASDAQ:SAVA) Shares Down 3.8% Cassava Sciences (NASDAQ:SAVA) Stock Price Down 3.8%September 18, 2024 | marketbeat.comCassava Sciences inks consulting pact with ex-CEO Remi BarbierSeptember 18, 2024 | msn.comCassava Sciences (NASDAQ:SAVA) Trading Up 10.8%Cassava Sciences (NASDAQ:SAVA) Shares Up 10.8%September 17, 2024 | marketbeat.comFortified bouillon cubes are seen as a way to curb malnutrition in Africa as climate worsens hungerSeptember 17, 2024 | msn.com15 of the Most Dangerous Foods on the PlanetSeptember 16, 2024 | msn.comCassava Sciences Names Rick Barry as Chief Executive OfficerSeptember 10, 2024 | markets.businessinsider.com Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Why buying gold might be a mistake (Ad)Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level. If you're interested, check out the recording here while the link's still up. SAVA Media Mentions By Week SAVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAVA News Sentiment▼0.490.56▲Average Medical News Sentiment SAVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAVA Articles This Week▼35▲SAVA Articles Average Week Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Collegium Pharmaceutical News Today Nature's Sunshine Products News Today Verastem News Today Chimerix News Today Fortress Biotech News Today Verrica Pharmaceuticals News Today Immunovant News Today ADMA Biologics News Today Organon & Co. News Today TG Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAVA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
